Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Raltegravir
Drug ID BADD_D01905
Description Raltegravir is an antiretroviral drug produced by Merck & Co., used to treat HIV infection. It received approval by the U.S. Food and Drug Administration (FDA) on 12 October 2007, the first of a new class of HIV drugs, the integrase inhibitors, to receive such approval.
Indications and Usage For the treatment of HIV-1 infection in conjunction with other antiretrovirals.
Marketing Status Prescription
ATC Code J05AJ01
DrugBank ID DB06817
KEGG ID D06676
MeSH ID D000068898
PubChem ID 54671008
TTD Drug ID D0I1FQ
NDC Product Code 65977-0049; 70518-1621; 17381-749; 68071-2113; 0006-3080; 0006-0477; 0006-0473; 0006-0227; 50090-1085; 0006-3603
Synonyms Raltegravir Potassium | Potassium, Raltegravir | Raltegravir | MK 0518 | 0518, MK | MK0518 | MK-0518 | Isentress
Chemical Information
Molecular Formula C20H21FN6O5
CAS Registry Number 518048-05-0
SMILES CC1=NN=C(O1)C(=O)NC(C)(C)C2=NC(=C(C(=O)N2C)O)C(=O)NCC3=CC=C(C=C3)F
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Cholestasis09.01.01.0010.011331%Not Available
Cleft lip15.11.05.002; 07.05.08.002; 03.11.05.0020.011331%Not Available
Completed suicide19.12.01.001; 08.04.01.0100.002956%Not Available
Constipation07.02.02.001--
Cough22.02.03.001--
Death08.04.01.001--
Dehydration14.05.05.001--
Depression19.15.01.0010.033992%
Dermatitis allergic23.03.04.003; 10.01.03.0140.007554%Not Available
Diabetes mellitus14.06.01.001; 05.06.01.0010.015108%Not Available
Diabetic ketoacidosis14.07.03.001; 05.07.03.0010.011331%Not Available
Diarrhoea07.02.01.0010.105753%
Disseminated tuberculosis11.04.01.0010.007554%Not Available
Dizziness24.06.02.007; 17.02.05.003; 02.01.02.004--
Dyspepsia07.01.02.001--
Dysphagia07.01.06.0030.181291%
Dyspnoea22.02.01.004; 02.01.03.002--
Embolic stroke24.01.04.010; 17.08.01.0320.001971%Not Available
Eosinophilia01.02.04.0010.015108%
Erythema23.03.06.001--Not Available
Face oedema23.04.01.004; 10.01.05.002; 08.01.07.0030.011331%
Fatigue08.01.01.002--
Feeling abnormal08.01.09.014--Not Available
Femur fracture15.08.03.003; 12.04.01.0030.007554%Not Available
Flatulence07.01.04.0020.018884%
Gamma-glutamyltransferase increased13.03.01.0110.001971%
Gastric ulcer07.04.03.0020.007554%
Gastritis07.08.02.001--
Gastrooesophageal reflux disease07.02.02.0030.007554%
Gastroenteritis11.01.07.004; 07.19.03.0010.002956%Not Available
The 2th Page    First    Pre   2 3 4 5 6    Next   Last    Total 8 Pages